ARL6IP4

Across TCGA pan-cancer cohorts, ARL6IP4 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of ARL6IP4’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where ARL6IP4 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types ARL6IP4 is over-expressed in tumor, although a few such as PDAC show the opposite, repressed pattern.

LUAD, LSCC, and PDAC are the cancer types where ARL6IP4 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ARL6IP4 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Female	III,IV	+0.530	<.001	9	view →
LSCC	Male	All	+0.335	<.001	8	view →
PDAC	Female	All	−0.390	<.001	7	view →
COAD	All	II,III,IV	+0.115	.004	5	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

ARL6IP4–LUAD

Open the LUAD breakdown →